SOURCE: Cutting Edge Information

Cutting Edge Information

November 03, 2009 12:13 ET

Cutting Edge Information Sees Burst of Innovation From Pharma and Biotech, Studies Regulatory Atmosphere

RESEARCH TRIANGLE PARK, NC--(Marketwire - November 3, 2009) - The pharmaceutical and biotechnology industries are on the verge of both a burst of innovative new products and a change in mindset from stereotypical "pill pushers" to breaking through to the vanguard of healthcare solution providers, according to recent work by business research firm Cutting Edge Information (CEI).

In addition to other recent positive developments across the life sciences industries, yesterday's call from Eli Lilly Chief Executive Officer John Lechleiter for the industry to "reinvent innovation" ( is another towering guidepost for all companies to continue producing new medicines and treatments and to better communicate the benefits that the industry brings to society.

CEI's research over the last decade has shown swings in both the industry's approach to driving new drug development and communicating the value of that work to the world's health. As regulatory pressure has increased because of overall healthcare changes, the industry has clarified and strengthened its message. While progress has been made in educating various stakeholders, including physicians, patients and payers, much work remains to be done.

"No other industry has to balance the massive dual challenges of public demand for rapid innovation and sometimes 'miracle' cures with such incredibly strict regulatory oversight," said Jason Richardson, president of CEI. "Of course, both of those demands are understandable -- people want to see the fruits of science, particularly when a loved one's health is at stake, but they also want the government and industry's assurances that these advances are not going to do more harm than good."

Across various therapeutic areas (, companies are making advances into ever more complicated science. And every company is working to make its clinical development, medical affairs, patient education and lifecycle management programs more productive, both for shareholder value and for the efficiency of the overall healthcare system ( ).

"Pharmaceuticals and Biotechnology have faced an especially tough wave of specific issues that have clouded their picture," said Adam Bianchi, chief operating officer of CEI. "Some of that externally driven cloud has lifted, and now companies are plotting the strategies that will really let them clear the smoke and blaze productive paths forward to 2011, 2015, and beyond."

Contact Information

  • For more information, please contact:
    Stephanie Swanson
    Email Contact